Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML

Kampen, K R; ter Elst, A; Mahmud, H; Scherpen, F J G; Diks, S H; Peppelenbosch, M P; de Haas, V; Guryev, V; de Bont, E S J M
March 2014
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p589
Academic Journal
Single kinase-targeted cancer therapies often failed prolonged responses because cancer cells bypass through alternative routes. In this study, high-throughput kinomic and proteomic approaches enabled to identify aberrant activity profiles in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) that defined druggable targets. This approach revealed impaired activity of proteins belonging to the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathway. Pharmacological druggable MAPK pathway targets tested in primary MLL-rearranged AML included MAPKK1/2 (MEK), cyclic AMP-responsive element-binding protein (CREB) and MAPK8/9 (JNK). MEK inhibition showed to severely decrease MLL-rearranged AML cell survival without showing cytotoxicity in normal controls, whereas inhibition of CREB and JNK failed to exhibit MLL selectivity. Exploring the working mechanism of MEK inhibition, we assessed proteome activity in response to MEK inhibition in THP-1. MAPK1/3 (Erk) phosphorylation was instantly decreased in concurrence with a sustained Akt/mammalian target of rapamycin (mTOR) phosphorylation that enabled a subpopulation of cells to survive MEK inhibition. After exhaustion of MEK inhibition the AML cells recovered via increased activity of vascular endothelial growth factor receptor-2 (VEGFR-2) and Erk proteins to resume their proliferative state. Combined MEK and VEGFR-2 inhibition strengthened the reduction in MLL-rearranged AML cell survival by blocking the Akt/mTOR and MAPK pathways simultaneously. The generation of insights in cancerous altered activity profiles and alternative escape mechanisms upon targeted therapy allows the rational design of novel combination strategies.


Related Articles

  • Blood: Drug makes leukemia more vulnerable to chemo.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article focuses on study in which researchers have shown that a new drug makes chemotherapy more effective in treating acute myeloid leukemia which helps in driving cancer cells out of the bone marrow and into the bloodstream, where they are more vulnerable to chemotherapy.

  • Acute Leukemia.  // Current Medical Literature: Leukemia & Lymphoma;2013, Vol. 21 Issue 4, p119 

    A review of the article "Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study," by A. Shah and colleagues, which appeared in the periodical "British Journal of Haematology" in the 2013 issue, is presented.

  • TREATMENT GOAL FOR ACUTE MYELOID LEUKEMIA.  // Clinical Advisor;Sep2010, Vol. 13 Issue 9, p61 

    The article presents an answer to a question related to the treatment goal of a man with acute myeloid leukemia (AML) who also has other health problems.

  • Hematology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS31 

    Presents an abstract of the research manuscript `High dose Ara-C versus intermediate dose Ara-C as consolidation in adult AML: 5 year follow-up,' by M.K. Gandhi, M. Crump and A. Keating. Acute myelocytic leukemia (AML).

  • Differentiation therapy in acute myelogenous leukemia (non-APL). Waxman, S // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p491 

    Successful treatment of acute promyelocytic leukemia (APL) has identified several novel approaches to induce leukemic cell differentiation and selective apoptosis by overcoming the site-specific transcriptional repression by dominant fusion leukemogenic proteins characteristic of APL and other...

  • Treatment of relapsed and refractory acute myelogenous leukemia. Estey, E H // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p476 

    Evidence suggests that the salvage therapy utilized for relapsed and refractory acute myelogenous leukemia (AML) should differ based on the duration of a patient's complete remission (CR), the principal predictor of outcome. While standard regimens have produced higher CR rates than...

  • Antidepressant as Cancer Treatment….  // BioWorld Today;3/19/2012, Vol. 23 Issue 43, Special section p1 

    The article reports that Vesanoid, combined with an antidepressant, can treat some other types of acute myeloid leukemia (AML), according to the British Institute for Cancer Research.

  • Removal of Abnormal Clone of Leukaemic Cells by Splenectomy. Gomez, G.; Hossfeld, D.K.; Sokal, J.E. // British Medical Journal;5/24/1975, Vol. 2 Issue 5968, p421 

    Reports the removal of chronic myelocytic leukemia (CML) by splenectomy. Characteristics of CML; Abnormality in Philadelphia chromosomes; Recurrence of karyotypic abnormalities found in splenic specimen; Application of chemotherapy and immunotherapy.

  • Marlene's story. Paulson, Marlene // Alive;Jul2013, Issue 369, p3 

    A personal narrative is presented which explores the author's experience of being treated for acute myelogenous leukemia at Dr. Castillo's Clinic in Tijuana, New Mexico.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics